Stable pharmaceutical composition containing desloratadine
Stable pharmaceutical compositions for oral administration are provided comprising an anti-allergic effective amount of descarbonylethoxy-loratadine or a pharmaceutically acceptable salt thereof, a lactose-based excipient and a pharmaceutically acceptable filler wherein the composition is substantially free of a pharmaceutically acceptable basic salt and wherein the composition contains less than about 1% by weight of N-formyl descarbonylethoxyloratadine after storage at a temperature of from about 25° C. to about 40° C. and a relative humidity of about 60% to about 75% for at least 1 month. Also provided are stable pharmaceutical compositions for oral administration comprising an anti-allergic effective amount of descarbonylethoxy-loratadine or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable filler wherein the composition is substantially free of a pharmaceutically acceptable basic salt and a lactose-based excipient and wherein the composition contains less than about 1% by weight of N-formyl descarbonylethoxyloratadine after storage at a temperature of from about 25° C. to about 40° C. and a relative humidity of about 60% to about 75% for at least 1 month.
1 . A stable pharmaceutical composition for oral administration comprising an anti-allergic effective amount of descarbonylethoxy-loratadine or a pharmaceutically acceptable salt thereof, a lactose-based excipient and a pharmaceutically acceptable filler, wherein the composition is substantially free of a pharmaceutically acceptable basic salt and wherein the composition contains less than about 1% by weight of N-formyl descarbonylethoxyloratadine after storage at a temperature of from about 25° C. to about 40° C. and a relative humidity of about 60% to about 75% for at least 1 month.
2 . The stable pharmaceutical composition of claim 1 , wherein the composition contains less than about 1% by weight of N-formyldescarbonylethoxyloratadine after storage at about 25° C. and about 60% relative humidity for at least 1 month.
3 . The stable pharmaceutical composition of claim 1 , wherein the composition contains less than about 0.5% by weight of N-formyldescarbonylethoxyloratadine after storage at about 25° C. and about 60% relative humidity for at least 1 month.
4 . The stable pharmaceutical composition of claim 1 , wherein the composition contains less than about 1% by weight of N-formyldescarbonylethoxyloratadine after storage at about 30° C. and about 65% relative humidity for at least 1 month.
5 . The stable pharmaceutical composition of claim 1 , wherein the composition contains less than about 0.5% by weight of N-formyldescarbonylethoxyloratadine after storage at about 30° C. and about 65% relative humidity for at least 1 month.
6 . The stable pharmaceutical composition of claim 1 , wherein the composition contains less than about 1% by weight of N-formyldescarbonylethoxyloratadine after storage at about 40° C. and about 75% relative humidity for at least 1 month.
7 . The stable pharmaceutical composition of claim 1 , wherein the composition contains less than about 0.5% by weight of N-formyldescarbonylethoxyloratadine after storage at about 40° C. and about 75% relative humidity for at least 1 month.
8 . The stable pharmaceutical composition of claim 1 , wherein the lactose-based excipient is selected from the group consisting of lactose, anhydrous lactose, lactose monohydrate and combinations thereof.
9 . The stable pharmaceutical composition of claim 1 , wherein the filler is a water-insoluble starch product.
10 . The stable pharmaceutical composition of claim 1 , wherein the filler is selected from the group consisting of modified starches, agglomerated starches, granulated starches, pregelatinized starches and combinations thereof.
11 . The stable pharmaceutical composition of claim 1 , wherein the filler is selected from the group consisting of Starch 1500, potato starch, corn starch, wheat starch, and mixtures thereof.
12 . The stable pharmaceutical composition of claim 1 , in a solid dosage form.
13 . A stable pharmaceutical composition for oral administration comprising an anti-allergic effective amount of descarbonylethoxy-loratadine or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable filler wherein the composition is substantially free of a pharmaceutically acceptable basic salt and a lactose-based excipient and wherein the composition contains less than about 1% by weight of N-formyl descarbonylethoxyloratadine after storage at a temperature of from about 25° C. to about 40° C. and a relative humidity of about 60% to about 75% for at least 1 month.
14 . The stable pharmaceutical composition of claim 13 , wherein the composition contains less than about 0.5% by weight of N-formyldescarbonylethoxyloratadine after storage at about 25° C. and about 60% relative humidity for at least 1 month.
15 . The stable pharmaceutical composition of claim 13 , wherein the composition contains less than about 0.1% by weight of N-formyldescarbonylethoxyloratadine after storage at about 25° C. and about 60% relative humidity for at least 1 month.
16 . The stable pharmaceutical composition of claim 13 , wherein the composition contains less than about 0.5% by weight of N-formyldescarbonylethoxyloratadine after storage at about 30° C. and about 65% relative humidity for at least 1 month.
17 . The stable pharmaceutical composition of claim 13 , wherein the composition contains less than about 0.1% by weight of N-formyldescarbonylethoxyloratadine after storage at about 30° C. and about 65% relative humidity for at least 1 month.
18 . The stable pharmaceutical composition of claim 13 , wherein the composition contains less than about 0.5% by weight of N-formyldescarbonylethoxyloratadine after storage at about 40° C. and about 75% relative humidity for at least 1 month.
19 . The stable pharmaceutical composition of claim 13 , wherein the composition contains less than about 0.1% by weight of N-formyldescarbonylethoxyloratadine after storage at about 40° C. and about 75% relative humidity for at least 1 month.
20 . The stable pharmaceutical composition of claim 13 , in a solid dosage form.
21 . The stable pharmaceutical composition of claim 13 , in a form of a tablet, a caplet, a capsule, a suspension tablet, a troche, or a powder.
22 . The stable pharmaceutical composition of claim 13 , further comprising one or more pharmaceutically acceptable excipients.
23 . The stable pharmaceutical composition of claim 13 , further comprising a lubricant.
24 . The stable pharmaceutical composition of claim 13 , wherein the filler is selected from the group consisting of microcrystalline cellulose, dicalcium phosphate, mannitol and combinations thereof.